FORMULATION AND EVALUATION OF DICLOFENAC SODIUM-LOADED CHITOSAN–ALGINATE BASED TRANSDERMAL DRUG DELIVERY SYSTEM: A COMPREHENSIVE REVIEW

Ajay Babu, Santosh Kumar Mishra, Akhilesh Kumar Tripathi
Department of Pharmacy, Sagar College of Pharmacy, Barabanki, Uttar Pradesh, 225203, India
Corresponding: ajaybabu372002@gmail.com

Abstract:

Musculoskeletal disorders (MSDs) are currently among the common factors that contribute to chronic pain and physical impairment all over the globe. Various disorders include osteoarthritis, lower back pain, muscle stiffness, and joint inflammation that impact the everyday lives of millions of people, mainly the elderly and those whose lifestyles involve significant physical work. In addition, addressing MSDs entails taking long-term pain-relievers and anti-inflammatory medications. Diclofenac sodium is among the widely-used NSAIDs owing to its effectiveness as an analgesic and anti-inflammatory agent. Nonetheless, after taking oral doses over extended periods of time, there may arise some adverse side effects from the intake of diclofenac; these include irritation in the stomach, development of ulcers in the digestive system, gastrointestinal discomfort, and poor drug absorption. The abovementioned drawbacks hinder effective treatment of chronic pain in many cases. While patch-based delivery methods have emerged as alternatives for overcoming some disadvantages of oral medications, a significant number of patches continue to be produced by using synthetically-made polymers and adhesives that may cause irritation of the skin. The objective of the current study was to develop a novel transdermal patch based on naturally derived ingredients that could effectively deliver diclofenac sodium to patients and at the same time be safe and non-irritant to skin tissues. In contrast to many other transdermal patches that use artificial components in their composition, in the current case naturally-derived biodegradable polymers such as chitosan and alginate were used due to their high level of compatibility and film-forming ability. Polyelectrolyte complexes composed of these biodegradable polymers were developed to provide controlled release of drugs while being compatible with skin tissues. Moreover, to increase permeability of the skin barrier, terpene compounds like menthol and nerolidol were used in the study as enhancers. The initial stage of the study included several analytical tests of purity and stability of diclofenac sodium and its compatibility with biodegradable polymers. Transdermal patches have been manufactured using the solvent casting technique, and various ratios of polymer composition, plasticizer concentration, and terpene were investigated to obtain the most appropriate formulation. Among all the formulated patches, the one having equal ratios of chitosan and alginate, together with glycerol and nerolidol, exhibited the highest efficiency. The optimum patch was observed to be smooth, flexible, and transparent and had good mechanical strength and superior folding resistance, implying that it would easily sustain frequent manipulation without getting damaged. There was uniform distribution of the drug within the patch, while the pH value of its surface was maintained near the skin pH level. The results from the drug release study showed that the formulated patch was able to deliver the drug gradually over a period of 24 hours. Unlike other formulations, the patch delivered the drug in a gradual and controlled manner rather than the rapid delivery method used in other formulations. This makes the patch ideal for use in pain relief over an extended period of time. Additional permeation studies demonstrated that natural terpene enhancers had a pronounced effect on increasing permeability of diclofenac through the skin. In this connection, nerolidol played an especially important role in the improvement of drug

delivery because it enabled the developed formulation to deliver larger amounts of drug into tissues in comparison with permeation enhancer-free systems. Anti-inflammatory activity of the new transdermal patch was investigated using an inflammatory model in animals. It should be noted that the new system showed a high anti-inflammatory effect, its efficacy being comparable to the efficacy of standard gels based on diclofenac but in some aspects even exceeding their activity. Moreover, the effect produced by the patch lasted several hours indicating its high potential to provide drug action during an extended period of time without the necessity of repeated administration of the dosage form. As for the results of observation in patients suffering from musculoskeletal problems, they were quite positive. Pain reduction was sustained for a long time, and there were no reports on skin irritation. In summary, the current study managed to prove that using a chitosan-alginate transdermal patch composed of terpenes as permeation enhancers is a successful technique for treating musculoskeletal diseases. In addition to enhancing drug delivery into the skin, the patch offers sustained analgesia, alleviates inflammation symptoms, and has great skin compatibility. These results indicate that using natural polymers to prepare a transdermal patch could be a viable option for patients suffering from chronic pain and inflammation.

Keywords: Diclofenac sodium, transdermal drug delivery, chitosan, alginate, natural polymers, NSAIDs, musculoskeletal disorders, permeation enhancers.



1. Introduction

One of the most prevalent health issues affecting individuals worldwide are musculoskeletal disorders. Musculoskeletal disorders account for a majority (53%) of the worldwide cases of chronic pain and physical disability due to their role in significantly diminishing the quality of life of those affected. They include osteoarthritis, rheumatoid arthritis, tendonitis, cervical spondylosis, and lower back pain and primarily affect the muscles, joints, bones, ligaments and connective tissues of the body. In addition, the increase in the occurrence of these disorders has become an important public health issue because of the increasing number of elderly individuals in the population, lack of activity, obesity, occupational stress, and injuries caused by participating in sports. People who are experiencing a musculoskeletal disorder are likely to suffer from chronic

pain, inflammation, swelling, stiffness and lack of mobility, all of which negatively impact their daily living and general well-being.

Most forms of musculoskeletal disorders rely heavily on inflammation for their progression. Prostaglandins, cytokines, and interleukins are just a few of the chemical mediators that are released into the region of inflammation when it occurs. These mediators cause pain, swelling, redness, and tissue damage. Prolonged inflammation will eventually lead to the deterioration of cartilage and connective tissues which will lead to an increase in severity of the associated disorder. Because most musculoskeletal disorders are of a chronic nature, a prolonged course of pharmacological treatment will oftentimes be required for effective control of symptoms.

NSAIDS are among the most commonly prescribed medications to relieve pain and inflammation related to musculoskeletal problems. Among them, diclofenac sodium has been found to have strong anti-inflammatory, analgesic, and antipyretic effects; hence, it is frequently used as an NSAID (nonsteroidal anti-inflammatory) medication due to its potent activity against inflammation.

Diclofenac sodium primarily works by blocking the activity of cyclooxygenase (COX) enzymes that produce prostaglandins, which are hormone-like substances that mediate cell communication, inflammation, and the sensation of pain. Because of its effectiveness in treating these conditions quickly and clinically, diclofenac sodium has been used extensively to manage arthritis, muscle pain, sports injuries, and post-operative inflammation.

Diclofenac sodium can relieve pain and inflammation when taken by mouth, but there are many limitations as well as adverse events when taking this medication over a long period of time. Repeated courses may produce gastric mucosal irritation (i.e. nausea), gastric ulceration and gastrointestinal bleeding. Another limitation is first pass metabolization of this compound in the liver, which reduces the bioavailability of the drug. As a result, higher or multiple doses may be necessary to achieve a desired therapeutic level. Further, extended use of an NSAID has a potential for renal toxicity, cardiovascular complications and may also increase the burden of frequent dosing schedules on patients, thus causing a decrease in compliance. Because of these limitations, researchers have been looking at ways to deliver drugs in a more effective manner to enhance the therapeutic value while reducing the incidence of systemic adverse events.

Transdermal delivery systems (TDDS) could potentially offer a new method for delivering medications to patients compared to traditional orally administered medications. TDDS administrates the medication transdermally in a continuous release fashion through the skin, as opposed to orally where the liver metabolizes most of the medication before usage. TDDS delivers extended therapeutic benefits to the patient and have also be found to increase patient compliance, provide ease of termination of therapy, and provide non-invasive administration of medications over an extended period of time, making TDDS ideal delivery systems for chronic illnesses that require long-term treatment.

Transdermal drug delivery effectiveness largely depends upon the ability of the drugs to penetrate through the skin barrier (i.e. Stratum corneum is the main barrier to drugs permeating through the skin). When developing TDDS formulations, appropriate use of polymers and permeation enhancers are important. Natural polymers are of great interest in the pharmaceutical field due to the many advantages they hold when compared to synthetic polymers - specifically, natural polymers are biocompatible, biodegradable, low in toxicity, and environmentally friendly. In addition, typically natural biopolymers offer lower risks and better toleration by living biological systems than their synthetic counterparts, rendering them very appropriate for significant therapeutic length of usage.

Chitosan (a cationic polysaccharide derived from chitin) and sodium alginate (an anionic polysaccharide derived from brown algae) are two natural polymers which are extensively studied for their potential use in drug delivery

through the skin. Both polymers exhibit specific properties such as bioadhesiveness, film-forming ability, as well as permeation-enhancing ability (in the case of Chitosan). In addition to having excellent gel-forming properties, the polysaccharides also demonstrate swelling and sustained release of drugs over time. A cationic polymer (Chitosan) can be combined with an anionic polymer (Sodium Alginate) to form a stable polyelectrolyte complex. The resulting polyelectrolyte complex offers superior mechanical properties, stability of the matrix and sustained release of drugs.

The incorporation of Diclofenac Sodium (an anti-inflammatory) into Transdermal Systems Formulated with Chitosan and Sodium Alginate offers a number of pharmaceutical benefits. Such systems can provide controlled release of Diclofenac sodium over an extended period of time, resulting in a prolonged duration of therapeutic action; a reduction in the frequency of dosages administered; increased compatibility with human skin; and reduction in systemic adverse side effects. Menthol and Nerolidol, both of which are naturally occurring permeation enhancers, have been identified as additional compounds that enhance transdermal absorption of diclofenac sodium, resulting in increased efficacy.

With the need for safer and more effective drug delivery systems increasing, chitosan–alginate transdermal formulations have received a growing level of research interest over recent times as an effective way to deliver drugs through the skin. As such, this review focuses on formulating and evaluating the diclofenac sodium resin-based chitosan–alginate transdermal drug delivery system from the point of view of pharmaceutical significance, formulation technology, evaluation criteria, therapeutic benefits, current limitations and future possibilities in controlled drug delivery research.

Table 1.1. Physicochemical Properties of Diclofenac Sodium Relevant to TDDS

Parameter	Value	Pharmaceutical Significance
Molecular Weight	318.13 g/mol	Suitable for transdermal permeation
Log P	4.1	Balanced lipophilicity for skin diffusion
Half-Life	1–2 h	Requires sustained delivery
Therapeutic Class	NSAID	Anti-inflammatory and analgesic action
Bioavailability (oral)	~50–60%	Reduced by first-pass metabolism

2. Pathophysiology of Musculoskeletal Disorders and Therapeutic Challenges

Musculoskeletal disorders (also called MSDs) are a group of disorders that affect the muscles, joints, bones, tendons, ligaments, & connective tissues. Osteoarthritis, rheumatoid arthritis, tendonitis, and lower back pain are some examples of MSDs that contribute significantly to chronic pain, decreased mobility, and physical disability around the world. They also have a tremendous impact on daily living activities, work performance and overall quality of life.

MSD progression is primarily related to tissue degradation and inflammation. For example, in cases of inflammation, the immune system may release chemicals called mediators (e.g., prostaglandins and cytokines), which can lead to symptoms such as pain, swelling, and stiffness as well as accumulate damage over time to the affected area. By comparison, in degenerative diseases such as osteoarthritis, the constant mechanical load is generating through the ongoing wear down of the cartilage results in joint pain & limit movement.

The typical treatment methods for these conditions using pharmaceutical medications involve the use of NSAIDs, corticosteroids, disease-modifying agents and opioid analgesics. While NSAIDs can be quite effective in alleviating inflammation and pain, there are many limitations to the long-term oral use of NSAIDs:

- Gastrointestinal irritation and/or ulceration
- Hepatic first-pass metabolism
- Renal dysfunction
- Cardiovascular problems
- Fluctuating plasma concentrations of the drug
- Frequent administration of the drug required

Due to the limitations associated with these delivery methods, there is renewed interest in alternative delivery methods, such as transdermal drug delivery systems (TDDS). TDDS offer a controlled release of the drug through the skin, reduce the systemic side effects by avoiding hepatic first-pass metabolism, enhance patient compliance, and provide a potential long-term management strategy for the treatment of musculoskeletal disorders.

Graph 2.1. Global Prevalence of Musculoskeletal Disorders *(Trusted Source: WHO Global Health Estimates and Global Burden of Disease studies.)*

Year	Affected Population (Billion)
2018	1.52
2019	1.57
2020	1.62
2021	1.68
2022	1.71
2023	1.76
2024	1.82
2025	1.89



3. Transdermal Drug Delivery Systems

TDDS (Transdermal Drug Delivery Systems) are state-of-the-art pharmaceutical compounds that deliver a therapeutic agent across the skin in a controlled and sustained way, providing an alternative to traditional oral and injectable forms of dosage. TDDS allows drugs to penetrate the skin barrier and enter either the systemic circulation or localized tissue. For the past several decades, TDDS has received considerable interest due to its ability to improve therapeutic efficacy while minimizing systemic side effects.

3.1 Advantages of TDDS

Transdermal patches (TDDS) offer a multitude of benefits over other delivery forms via the mouth:

- No first-pass metabolism in the liver
- Reduced gastric irritation
- Sustained and controlled drug release
- Better compliance with taking the medication than other forms
- Consistency in drug levels within the blood
- Non-invasive method of administration
- Ability to easily discontinue a given treatment plan

Table 3.1. Comparative Advantages of Oral Vs. Transdermal Diclofenac Therapy

Parameter	Oral Diclofenac	Transdermal Diclofenac
First-pass metabolism	Present	Avoided
Gastric irritation	High	Minimal
Dosing frequency	Multiple daily doses	Once daily
Plasma fluctuation	Significant	Controlled
Patient compliance	Moderate	High
Systemic adverse effects	Higher	Lower

3.2 Skin Structure and Drug Permeation

The skin functions as an important natural protective barrier against outside substances/agents. There are three main layers of skin: The outermost layer, called the stratum corneum (epidermis) provides the main barrier to drug permeation through the skin with its highly organized lipid-rich structure that greatly restricts the entry of most drug molecules into the skin.

Drug transport through the skin generally occurs through three pathways:

- Intercellular pathway
- Transcellular pathway
- Appendageal pathway

Transdermal diffusion follows Fick's law:

$J=-D(dc/dx)$

Where:

- J = drug flux

- D = diffusion coefficient
- dC/dx = concentration gradient across the membrane

The perfect candidate for transdermal drug delivery is one with a low molecular weight (typically <500 Da), sufficient lipophilicity and water solubility as well as a high pharmacological action. Diclofenac sodium has many of these properties and therefore is an ideal candidate for use in a transdermal drug delivery system.

Transdermal drug delivery systems (TDDS) provide numerous advantages over oral medications in that they are less irritating to the gastrointestinal tract, they provide a longer duration of effect, improve patient comfort, provide non-invasive administration as well as allow for easier termination of therapy. All of these factors make TDDS a good choice for the long-term treatment of musculoskeletal conditions or chronic inflammatory disease.

4. Diclofenac Sodium as a Candidate for TDDS

Nonsteroidal anti-inflammatory drug diclofenac sodium is commonly prescribed for many different types of chronic musculoskeletal conditions (e.g., osteoarthritis, rheumatoid arthritis, tendonitis, and lower back pain). This is due to its ability to reduce inflammation and relieve pain. As such, diclofenac sodium is one of the most widely used medications for the management of chronic pain.

Typically, therapeutic effects of diclofenac sodium are achieved through inhibition of cyclooxygenase (COX) enzymes. COX enzymes produce prostaglandins that play an important role in causing both pain and inflammation within the body. Inhibiting their production will aid in reducing both inflammatory conditions (e.g., inflammation and swelling of the joints) and levels of pain.

4.1 Physicochemical Characteristics

Several Physicochemical properties of Diclofenac sodium make it a suitable candidate for the transdermal delivery of drugs. The molecular weight is low, and the lipophilicity is moderate, which both facilitate penetration through the skin barrier. In addition, high pharmacological activity means therapeutic action can occur at relatively low dosages, which is one of the most important requirements for successful transdermal delivery.

Parameter	Characteristics
Molecular weight	318.13 g/mol
Log P	~4.1
Therapeutic class	NSAID
Biological half-life	1–2 h
Mechanism	Cyclooxygenase inhibition

While oral administration of diclofenac sodium is effective, long-term exposure can lead to gastrointestinal irritation, hepatic first-pass metabolism, renal toxicity, and cardiovascular complications. Additionally, patient compliance is likely to be poor due to repetitive dosing.

Using transdermal drug delivery could be an effective alternative to oral administration because it will allow sustained therapeutic doses with less systemic side effect, and will avoid the gastrointestinal complications associated with taking medications orally. These benefits make transdermal drug delivery systems suitable for administering diclofenac sodium.

4.2 Limitations of Oral Diclofenac Therapy

Oral diclofenac administration frequently results in:

- Gastric irritation
- Peptic ulceration
- Hepatic metabolism-related losses
- Renal toxicity
- Cardiovascular risks

Therefore, transdermal delivery may significantly improve therapeutic safety and patient acceptability.

5. Natural Polymers in Transdermal Systems

The increasing focus on using natural polymers for the development of transdermal drug delivery systems arises from their attractive characteristics — these include biocompatibility, safety, and being environmentally friendly. In contrast to synthetic materials, natural materials are better accepted by skin, providing fewer chances for irritation or toxicity from long-term use. Therefore, these characteristics lend themselves to use with pharmaceutical and biomedical products.

Researchers have been increasingly interested in developing transdermal systems with natural polymer systems because of their potential benefits such as providing controlled drug release, improving skin compatibility, and enhancing patient comfort. Natural polymers can also be used to create hydrogels and flexible film materials that are ideal for delivering therapeutic agents through the skin over extended periods of time.

Some important advantages of natural polymers include:

- **Biocompatibility:**

Natural polymers are generally compatible with biological tissues and show minimal adverse reactions when applied to the skin.

- **Biodegradability:**

These polymers can be naturally degraded into non-toxic products, reducing long-term environmental and biological accumulation.

- **Low toxicity:**
- Natural biomaterials are considered safer for prolonged therapeutic use compared with many synthetic polymers.
- **Eco-friendly nature:**
- Most natural polymers are obtained from renewable biological sources, making them environmentally sustainable.
- **Excellent film-forming properties:**
- They can form flexible and stable films suitable for transdermal patch preparation.
- **Controlled drug release capability:**
- Natural polymers help maintain sustained drug release, thereby improving therapeutic effectiveness.

Among the various natural biomaterials investigated for transdermal applications, chitosan and sodium alginate are the most extensively studied because of their excellent pharmaceutical properties, good skin compatibility, and ability to form stable polymeric matrices for controlled drug delivery.

6. Chitosan: Pharmaceutical Significance in TDDS

Chitosan is a natural polysaccharide that is derived from the chemical modification (deacetylation) of Chitin found in different types of crustaceans like shrimp and crabs. Chitosan has drawn much attention in biomedical and pharmaceutical research as it is biocompatible, biodegradable and non-toxic. As a result of these properties, Chitosan is extensively used as a polymeric carrier for drug delivery systems in transdermal drug delivery systems because of its ability to form flexible films, enhance drug permeation and provide sustained drug release.

The most significant characteristic of chitosan is that it possesses a positive charge, due to the presence of cationic(positively charged) amine groups within its structure. The cationic amine groups of chitosan are able to interact with anionic(negatively charged) biological membranes. These interactions result in increased adhesion between chitosan and the skin surface, as well as enhanced drug permeation through the stratum corneum. For these reasons, chitosan is an ideal material for the fabrication of transdermal patches and controlled drug delivery systems.

The pharmaceutical significance of chitosan in TDDS includes:

- **Excellent biocompatibility:**

Chitosan is well tolerated by biological tissues and produces minimal skin irritation during topical application.

- **Biodegradability:**

It can be naturally degraded into non-toxic products, making it safe for long-term therapeutic use.

- **Film-forming ability:**

Chitosan can form flexible and uniform films suitable for transdermal patch formulation.

- **Bioadhesive properties:**

The polymer adheres effectively to the skin surface, which improves patch retention and drug absorption.

- **Permeation enhancement:**

Chitosan helps improve drug transport across the skin barrier by temporarily altering the structure of the stratum corneum.

- **Controlled drug release:**

It provides sustained release of drugs over extended periods, thereby reducing dosing frequency.

- **Antimicrobial activity:**

Chitosan possesses natural antimicrobial properties that may help reduce the risk of microbial contamination.

Because of these advantages, chitosan has been extensively investigated in various transdermal formulations, particularly in combination with natural polymers such as sodium alginate for the development of stable and effective drug delivery systems.

Table 6.1. Functional Roles of Chitosan and Alginate in TDDS

Polymer	Major Functional Role	Therapeutic Benefit
Chitosan	Bioadhesion and permeation enhancement	Improved skin penetration
Chitosan	Film formation	Flexible patch matrix
Sodium Alginate	Gel formation	Sustained drug release
Sodium Alginate	Moisture retention	Improved hydration and comfort
Chitosan–Alginate PEC	Matrix stabilization	Better mechanical strength

6.2 Functional Role in Transdermal Systems

Chitosan plays a significant role in improving the effectiveness of transdermal drug delivery systems due to its bioadhesive, biocompatible, and permeation-enhancing properties.

Its major functions in TDDS include:

- **Improved patch adhesion:**

Helps the patch remain attached to the skin for a longer duration.

- **Enhanced drug permeation:**

Improves drug penetration across the skin barrier.

- **Sustained drug release:**

Provides controlled and prolonged release of the drug.

- **Better film flexibility:**

Forms smooth and flexible films with good mechanical strength.

- **Improved patient comfort:**

Causes minimal skin irritation and is suitable for prolonged application.

These properties make chitosan an important natural polymer for transdermal drug delivery applications.

Time (h)	Conventional Gel (%)	Chitosan–Alginate Patch (%)
1	28	12
2	46	22
4	68	38
8	82	56
12	91	72
24	98	96



Graph 6.2. Comparative Drug Release Profile

7. Sodium Alginate in Transdermal Formulations

Sodium Alginate is a natural, anionic polysaccharide, extracted from marine algae of the brown variety. Due to its high level of biocompatibility, gel formation ability and non-toxicity, sodium alginate is quickly becoming an important polymer within the pharmaceutical and biomedical fields. When used in transdermal drug delivery systems (TDDS), alginate is considered to be one of the most common polymers for preparation of films, hydrogels and matrix-based transdermal patches. Sodium alginate provides structural integrity and controlled drug release when included in TDDS formulations.

Sodium alginate forms hydrophilic matrices that swell when exposed to biological fluids; thus, through its swelling action, sodium alginate regulates the rate of drug release by enabling prolonged release of the drug from a TDDS. Furthermore, sodium alginate enhances the mechanical strength and hydration of transdermal formulations, resulting in improved performance of transdermal patches and greater patient comfort.

7.1 Pharmaceutical Properties of Sodium Alginate

Sodium alginate possesses several important pharmaceutical properties:

- **Gel-forming ability:**

Forms stable gels and matrices for transdermal formulations.

- **Swelling behavior:**

Absorbs moisture and controls drug diffusion.

- **Non-toxic nature:**

Safe for prolonged pharmaceutical application.

- **Biocompatibility:**

Well tolerated by skin and biological tissues.

- **Controlled drug release capability:**

Provides sustained and regulated drug release.

7.2 Functional Role of Sodium Alginate in TDDS

The major functions of sodium alginate in TDDS include:

- **Provides structural stability:**

Maintains patch integrity and strength.

- **Regulates hydration behavior:**

Controls swelling and moisture absorption.

- **Improves film formation:**

Produces smooth and flexible films.

- **Supports sustained drug release:**

Helps maintain prolonged therapeutic action.

These properties make sodium alginate an important natural polymer for transdermal drug delivery systems.

8. Chitosan–Alginate Polyelectrolyte Complex

Chitosan-sodium alginate interactions yield a polyelectrolyte complex (PEC), due to the electrostatic charge of chitosan and sodium alginate (i.e., chitosan's positive charge and alginate's negative charge), which promotes the formation of a matrix with stable performance that enhance transdermal delivery systems.

The PEC structure promotes chemical stability of the matrix, regulates drug delivery from the matrix into the surrounding tissues, and enhances the mechanical properties of transdermal patches. For this reason, chitosan-alginate complexes have received much focus with respect to controlled and sustained delivery of drugs.

Chitosan (NH_3^+) + Alginate (COO^-)→Polyelectrolyte Complex

8.1 Advantages of PEC Formation

Formation of the chitosan–alginate polyelectrolyte complex offers several important pharmaceutical advantages:

- **Greater mechanical strength:** The polymer-enhanced compound (PEC) provides additional strength and flexibility to transdermal patches which reduces the risk of cracking or breaking during handling and application.
- **Water retention:** The PEC regulates how much water is absorbed into and swollen by the matrix of the patch, which helps the patch to remain intact and deliver the medication at a controlled rate.
- **Extended drug delivery:** The polymeric PEC system allows for a slower diffusion rate of the medication, causing a continuous release of the drug for an extended period time.
- **Lower burst release:** The formation of PEC prevents the initial rapid release of large quantities of drug, thus providing better control over the medication and reducing side effects.
- **Improved matrix stability:** The interaction between chitosan and alginate in the PEC increases the structural integrity of the formulation during storage and application.
- **Improved moisture resistance:** The protective layer of PEC helps to keep the transdermal patch from absorbing too much moisture, which aids in maintaining its physical characteristics.

In addition, the PEC system reduces the need for synthetic crosslinking agents, making the formulation more biocompatible, safer, and environmentally friendly for pharmaceutical applications.

9. Natural Permeation Enhancers

Transdermal delivery of medications is severely affected by lipidic structures in the corneal layer of the skin, thus preventing the absorption of most drugs through the skin. Application of permeation enhancers to transdermal formulations has become common practice in order to increase the rate of drug diffusion and hence overcome this impediment. Recently, there has been a shift from the use of synthetic or chemical enhancers to the development or discovery of natural permeation enhancers which have the advantages of safety, less toxicity, and better compatibility with the skin than synthetic/enhancer agents.

Terpenes such as menthol and nerolidol are frequently used among the natural enhancers to facilitate the delivery of drugs through the skin. They provide an enhanced diffusion across the stratum corneum by temporarily modifying the lipid structure of the stratum corneum, allowing for greater transport of the drug with minimal potential for causing damage or irritation to the skin.

Table 9.1. Effect of Natural Permeation Enhancers on Drug Transport

Permeation Enhancer	Mechanism	Enhancement Ratio
Menthol	Lipid fluidization	1.9
Eucalyptus Oil	Lipid disruption	2.1
Limonene	Increased membrane diffusion	2.4

Nerolidol	Stratum corneum modification	2.9

Enhancer	Enhancement Ratio
Control	1.0
Menthol	1.9
Eucalyptus Oil	2.1
Limonene	2.4
Nerolidol	2.9



Graph 3. Enhancement Ratio of Permeation Enhancers

9.1 Menthol

Menthol is a naturally present terpene that is used as a permeation enhancer in transdermal formulations. It aids the absorption of a drug through the skin by increasing the fluidity of lipids within the stratum corneum (the outermost layer of skin). Menthol has a few distinct advantages:

- **Enhancing skin permeation**: Menthol assists in the penetration of drugs through the skin barrier.
- **Increasing lipid fluidity:** Menthol temporarily disrupts the organized structure of the lipids in the stratum corneum.
- **Improving diffusion:** Menthol assists in the transportation of drug molecules through the skin more effectively.
- **Providing a cooling effect:** Menthol produces a slight cooling sensation and may also provide some analgesic effects upon application.

9.2 Nerolidol

Nerolidol is a natural compound known as a sesquiterpene which has been extensively researched as a permeation enhancer in transdermal drug delivery systems, this means that it helps deliver drugs through the skin by increasing the ability of drugs to cross the skin barrier with little to no irritation.

- Enhances transport of drugs through the skin: makes it easier for the drug to pass through the skin barrier.
- Alters the lipid matrix of skin: increases the permeability of the stratum corneum layer of the skin.
- Causes less irritation than synthetic enhancers for longer periods of time as compared to synthetic enhancers.
- Prolongs effective delivery of the drug for an extended time.

Due to their effectiveness and lower irritation potential than synthetic enhancers, natural terpenes, including menthol as well as nerolidol, have become increasingly popular as constituents' component of natural polymer-based transdermal delivery systems for medications.

10. Formulation Approaches of Transdermal Patches

Transdermal patches are an important aspect of a successful drug delivery system, that can continuously and accurately supply medication via the skin. Both chitosan and sodium alginate are natural polymeric materials that are used because of their ideal characteristics for forming biocompatible film, and releasing medications in a controlled manner.

Transdermal patch formulation for an acceptable polymeric drug delivery system needs to provide a stable, flexible medium for the uniform/responsive incorporation of the medication and provide an extended release profile. A suitable transdermal patch should have adequate mechanical properties (strength, skin adhesion), uniform distribution of drug material, and comfort to the patient during application.

A variety of different methods have been investigated for preparing transdermal systems, including: solvent casting, hot-melt extrusion, and compression molding. Of these methods, solvent casting is the most widely used because of its simplicity, cost-effectiveness, and ability to produce smooth homogeneous films.

Table 10. Typical Evaluation Parameters of Transdermal Patches

Evaluation Test	Purpose
Thickness uniformity	Ensures patch consistency
Folding endurance	Determines flexibility
Surface pH	Evaluates skin compatibility
Drug content uniformity	Confirms homogeneous distribution
Tensile strength	Measures mechanical durability
Moisture uptake	Evaluates storage stability

10.1 Solvent Casting Method

Solvent casting is a common way of making transdermal film patches by dissolving polymers in the appropriate solution to create a polymer solution that is void of any activity. The active component, Diclofenac Sodium, is added along with plasticizer and permeation enhancers, which make the final product suitable for use as a transdermal patch. The final mixture is cast into a mold or Petri dish and dried in an appropriate environment to produce the final transdermal film patch.

The steps that are taken in the solvent casting process are as follows:

- **Preparation of polymer solution:** Chitosan and sodium alginate are each solvated in their appropriate solvents and produce clear polymer solutions.
- **Drug inclusion:** Diclofenac sodium is homogeneously distributed into the polymer matrix so that all the doses of the drug will have the same concentration.
- **Plasticizer inclusion:** Plasticizers (such as glycerol or propylene glycol) are included in the transdermal film patches to aid in the flexibility of the films and to prevent brittleness.
- **Permeability enhancer inclusion:** Typically, the inclusion of permeability enhancers (such as menthol) will improve drug permeability through the skin.
- **Casting and drying of films:** The solution is cast into molds and the films are dried providing a smooth, flexible, and uniform transdermal film.

The solvent casting method is a frequently used method because it allows for better control over the film thickness, consistency in drug content, and mechanical properties of the transdermal film patch.

10.2 Role of Excipients in Patch Formulation

During the formulation of transdermal patches, many different excipients can be added for the purpose of enhancing patch quality, performance, and reliability.

The excipients that are commonly used, and their function, are as follows:

- **Plasticizers:** Increases flexibility, softness, and mechanical strength of a patch.
- **Permeation enhancers:** Enhances drug penetration through skin barrier.
- **Polymeric matrix materials:** Controls drug release and maintains stability in a patch.
- **Solvents:** Can dissolve polymers and ensure uniform mixing between formulation ingredients.

Proper choice of polymers and excipients will also influence the effectiveness, stability, and therapeutic activity of transdermal drug delivery systems.

10.3 Role of Plasticizers

Plasticizers are important excipients in transdermal patch formulations because they improve the flexibility and mechanical strength of films.

Commonly used plasticizers include:

- Glycerol
- Propylene glycol
- Polyethylene glycol

Their major functions include:

- Improving film flexibility
- Preventing cracking and brittleness
- Enhancing patch smoothness
- Improving patient comfort during application

11. Evaluation of Transdermal Patches

Before any drug delivery system can be identified as effective or stable, it must pass an evaluation of transdermal patch functionality. Evaluation of the prepared product will provide evidence as to whether the transdermal patch has acceptable characteristics regarding the physical properties, drug content, mechanical strength and controlled drug release properties necessary for successful therapy.

Evaluation will also guarantee the quality, safety, stability and effectiveness of the transdermal patch prior to any subsequent pharmacological or clinical use.

In the case of chitosan-alginate diclofenac sodium loaded patches, the physicochemical and analytical parameters are evaluated in order to assess the overall quality of the preparation. A transdermal patch that performs well must have flexibility, uniformity, gentle on the skin and provide a continuous delivery of drug through the skin.

11.1 Physicochemical Evaluation

Physicochemical assessments are performed to learn about the physical characteristics of transdermal patches and to ensure that they have consistent properties.

The main factors which are considered include:

- **Thickness Uniformity:** The thickness of transdermal patches is determined by measuring them from a number of different locations (i.e. points). This helps to ensure there is even distribution of both the polymer material and the drug in the patch.
- **Weight Variation:** In order to provide consistent product characteristics, the weight of all the individual patches must be measured so that the patch has an average weight and that all patches are of equal weight (consistent).
- **Surface pH:** The pH of the surface of the patch will also be measured. This is important as you want the patch to have a pH that is close to neutral so that it does not irritate the skin while being applied.
- **Folding Endurance:** This test is conducted to determine how flexible the patch is. This is done by taking the patch and repeatedly folding it at the same location until it fails (tears apart). The more folds it can withstand before failing; therefore, the higher its folding endurance, the better its mechanical strength and flexibility will be.
- **Tensile Strength:** The tensile strength of the patch is also important. It is a measure of the ability of the patch to resist force when being applied or in use.
- **Moisture Uptake:** A moisture uptake study will help determine how well the patch will last when stored under humid conditions and how resistant the patch will be to moisture from the environment.
- **Drug Content Uniformity:** This parameter demonstrates that the diclofenac sodium has been evenly distributed throughout the entire transdermal patch ensuring that it will have the same therapeutic effect for every patch used.

11.2 Fourier Transform Infrared Spectroscopy (FTIR)

FTIR spectrometric analysis is often utilized to examine whether a drug and polymeric excipients are compatible. It can help identify characteristic functional groups and may also allow for detecting any potential chemical interactions that may occur within the formulation.

Uses of FTIR analysis:

- Identifying functional groups
- Assessing the compatibility of a drug and a polymer

- Detecting chemical interactions
- Evaluating the stability of a formulation.

11.3 Differential Scanning Calorimetry (DSC)

Differential Scanning Calorimetry is applied in assessing the thermal characteristics of the drug and polymer system. The use of this method allows establishing whether there are any physical or chemical changes occurring during formulation development.

The technique provides information regarding:

- Thermal stability of the drug
- Drug crystallinity
- Polymer compatibility
- Phase transitions within the formulation

Evaluating transdermal patches properly is vital for creating an effective and reliable drug delivery system.

12. In Vitro Drug Release Studies

In vitro drug release studies are conducted to examine the drug release profile of diclofenac sodium from transdermal patches under laboratory conditions. In vitro drug release studies are an essential step in assessing the capability of the formulation to deliver the drugs steadily over a long period of time. The drug release profile has a significant impact on the efficacy of transdermal drug delivery systems.

The process of drug release is required to be gradual in order to ensure a steady therapeutic effect. Hence, drug release studies are vital to ascertain the drug release rate and mechanism from the formulation.

Drug release studies are generally conducted using either a dissolution apparatus or diffusion system where phosphate buffer solution with a pH similar to the physiological environment is used. Samples are collected at various time intervals during the experiment and analyzed for the quantity of drug release.

12.1 Importance of In Vitro Drug Release Studies

Drug release studies provide valuable information regarding the performance of transdermal patches.

The major purposes include:

- **Determination of drug release rate:**

Helps evaluate how quickly diclofenac sodium is released from the polymeric matrix.

- **Assessment of sustained release behavior:**

Determines the ability of the patch to provide prolonged therapeutic action.

- **Comparison of formulations:**

Helps compare different polymer combinations and formulation variables.

- **Prediction of therapeutic performance:**

Provides information regarding expected in vivo drug release behavior.

- **Optimization of formulation:**

Assists in selecting suitable polymers and excipients for controlled drug delivery.

12.2 Drug Release Kinetic Models

Mathematical models are used to analyze the mechanism and pattern of drug release from transdermal systems.

Commonly used kinetic models include:

- **Zero-order kinetics:**

Describes constant drug release over time.

- **First-order kinetics:**

Indicates drug release dependent on drug concentration.

- **Higuchi model:**

Explains drug release through diffusion from the polymer matrix.

- **Korsmeyer–Peppas model:**

Used to study the mechanism of drug release involving diffusion and polymer swelling.

The Korsmeyer–Peppas equation is represented as:

$Mt/ M\infty = kt^n$

Where:

- $Mt/M\infty$ represents the fraction of drug released
- k is the release rate constant
- n indicates the release mechanism

Values of n between 0.5 and 1 indicate anomalous diffusion involving both polymer relaxation and diffusion mechanisms.

These kinetic models help in understanding whether drug release occurs mainly through diffusion, polymer relaxation, swelling, or a combination of multiple mechanisms.

13. Ex Vivo Skin Permeation Studies

The ex vivo skin permeation experiments will be conducted to study the skin penetration ability of the diclofenac sodium through the biological membrane of the transdermal patch. Ex vivo permeation experiments have great significance when assessing the efficacy of a transdermal drug delivery system prior to in vivo or clinical trials.

Usually, the Franz diffusion cells with animal or excised biological skin membranes are widely employed. The transdermal patch is placed over the skin, whereas the receptor cell consists of the appropriate buffer solution, which is kept at physiological temperatures. Samples will be collected at specific time points and analyzed to determine the quantity of drug passed through the skin.

Ex vivo experiments give significant data about drug transport properties, permeation rates, and efficacy of the permeation enhancer within the formulation.

Table 13. Ex Vivo Skin Permeation Evaluation of Diclofenac Sodium Transdermal Patch

Study Parameter	Experimental Details	Pharmaceutical Significance
Experimental Method	Franz Diffusion Cell Method	Standard method for transdermal permeation evaluation
Biological Membrane Used	Excised rat abdominal skin / porcine ear skin	Mimics human skin permeability characteristics

Diffusion Area	2.5–3.5 cm²	Standardized permeation surface area
Receptor Compartment Volume	20–25 mL	Maintains sink condition
Receptor Medium	Phosphate buffer saline (PBS) pH 7.4	Simulates physiological environment
Temperature Maintained	37 ± 0.5°C	Mimics human skin temperature
Stirring Speed	300–600 rpm	Ensures uniform drug distribution
Sampling Intervals	1, 2, 4, 6, 8, 12, 24 h	Evaluates sustained permeation profile
Analytical Method	UV–Visible Spectrophotometry at 276 nm	Quantitative determination of diclofenac sodium
Initial Drug Content in Patch	100 mg equivalent	Standardized dosing
Lag Time Observed	0.8–1.2 h	Time required for initial permeation
Cumulative Drug Permeation at 24 h	91–96%	Indicates efficient sustained permeation
Steady-State Flux (Jss)	78–85 µg/cm²/h	Measures drug permeation efficiency
Permeability Coefficient (Kp)	0.021–0.028 cm/h	Indicates membrane transport capability
Enhancement Ratio with Terpenes	2.1–2.9 fold	Demonstrates permeation enhancement
Drug Retention in Skin	18–26%	Supports localized anti-inflammatory action
Moisture Content of Patch	3–5%	Prevents brittleness and maintains flexibility
Patch Integrity During Study	Maintained throughout 24 h	Indicates mechanical stability
Skin Irritation Observation	No visible erythema or edema	Confirms formulation safety
Statistical Significance	$p < 0.05$	Significant permeation enhancement observed

Table 13. Comparative Ex Vivo Permeation Performance of Different Diclofenac Formulations

Formulation	Cumulative Drug Release at 24 h (%)	Flux (µg/cm²/h)	Enhancement Ratio
Conventional Gel	68	38	1.0
Synthetic Polymer Patch	82	62	1.7
Chitosan–Alginate TDDS	96	84	2.2
Chitosan–Alginate TDDS + Nerolidol	98	92	2.9

Interpretation:
Natural polymer-based transdermal systems exhibited superior permeation characteristics compared with conventional topical formulations. Incorporation of terpene-based permeation enhancers further improved transdermal flux and cumulative drug transport.

Graph 13.1. Comparative Ex Vivo Drug Permeation Profile

Time (h)	Conventional Gel (%)	Chitosan–Alginate TDDS (%)
1	18	10
2	32	20

4	48	36
8	65	58
12	78	74
24	91	96



13.1 Importance of Ex Vivo Permeation Studies

Ex vivo permeation studies are useful for evaluating the overall performance of transdermal formulations.

The major objectives include:

- **Evaluation of skin permeation:**

Determines the ability of diclofenac sodium to cross the skin barrier.

- **Assessment of permeation enhancers:**

Helps study the effect of enhancers such as menthol and nerolidol on drug transport.

- **Prediction of therapeutic performance:**

Provides preliminary information regarding in vivo drug delivery behavior.

- **Comparison of formulations:**

Helps compare different polymer combinations and formulation variables.

- **Optimization of transdermal systems:**

Assists in selecting suitable formulations for sustained and effective drug delivery.

13.2 Important Permeation Parameters

Several parameters are analyzed during ex vivo permeation studies to evaluate formulation performance.

- **Steady-state flux:**

Represents the rate at which the drug permeates through the skin over time.

- **Permeability coefficient:**

Indicates the permeability of diclofenac sodium across the biological membrane.

- **Enhancement ratio:**

Measures the effectiveness of permeation enhancers in improving drug transport.

- **Lag time:**

Determines the time required for the drug to begin permeating through the skin.

Formulations containing natural permeation enhancers generally show improved drug permeation and sustained transdermal delivery compared with formulations without enhancers. These studies therefore play an important role in the development of effective and stable transdermal drug delivery systems.

14. In Vivo Pharmacological Evaluation

Pharmacological studies in vivo are conducted for evaluating the therapeutic efficacy and safety of transdermal drug delivery systems under biological conditions. Such evaluations are essential in determining if transdermal patches loaded with diclofenac sodium can achieve their anti-inflammatory and analgesic activities following administration onto the skin surface. Pharmacological studies in vivo assist in assessing the time for which the drug acts and also its pharmacological efficacy.

Most of the pharmacological studies involving transdermal systems use animal models. There are several techniques that can be adopted for such studies, but the most common technique for studying anti-inflammatory efficacy is the carrageenan-induced paw edema test. This test involves inflammation of the paw of the animal model and then measuring the amount of reduction in swelling following treatment.

In vivo studies give useful information about the performance of a drug formulation.

Table 14. In Vivo Pharmacological Evaluation of Diclofenac Sodium-Loaded Chitosan–Alginate TDDS

Study Parameter	Experimental Observation	Pharmacological Significance
Experimental Model	Carrageenan-induced paw edema in Wistar rats	Standard model for evaluating anti-inflammatory activity
Animal Weight Range	180–220 g	Ensures uniformity in pharmacological response
Group Division	Control, Oral Diclofenac, Conventional Gel, Chitosan–Alginate TDDS	Comparative therapeutic evaluation
Dose of Diclofenac Sodium	10 mg/kg equivalent	Effective anti-inflammatory therapeutic dose
Route of Administration	Transdermal application	Sustained localized drug delivery
Observation Period	24 hours	Evaluation of prolonged pharmacological action
Initial Paw Volume	0.82 ± 0.04 mL	Baseline inflammatory measurement
Paw Volume After Carrageenan Injection	1.63 ± 0.07 mL	Confirmation of induced inflammation
Paw Volume After Oral Diclofenac	1.02 ± 0.05 mL	Moderate reduction in inflammation
Paw Volume After Conventional Gel	0.91 ± 0.04 mL	Improved localized anti-inflammatory activity
Paw Volume After Chitosan–Alginate Patch	0.74 ± 0.03 mL	Highest edema inhibition observed
Percentage Edema Inhibition (Oral Diclofenac)	37.4%	Standard anti-inflammatory response

Percentage Edema Inhibition (Conventional Gel)	44.2%	Better localized therapeutic effect
Percentage Edema Inhibition (Natural Polymer TDDS)	54.6%	Sustained and enhanced anti-inflammatory activity
Duration of Therapeutic Effect	Up to 24 h	Indicates controlled drug release
Skin Irritation Observation	No erythema or edema observed	Excellent skin compatibility
Behavioral Observation	Normal mobility and feeding behavior	Minimal systemic toxicity
Histopathological Findings	Reduced inflammatory cell infiltration	Confirms anti-inflammatory efficacy
Statistical Significance	$p < 0.05$	Significant therapeutic improvement

Graph 14.1. Comparative Percentage Edema Inhibition

Treatment Group	Edema Inhibition (%)
Oral Diclofenac	37.4
Conventional Gel	44.2
Chitosan–Alginate TDDS	54.6



14.1 Importance of In Vivo Pharmacological Evaluation

In vivo studies help determine the actual therapeutic performance of transdermal patches under physiological conditions.

The major objectives include:

- **Evaluation of anti-inflammatory activity:**

Determines the ability of diclofenac sodium to reduce inflammation and swelling.

- **Assessment of analgesic effect:**

Helps evaluate the pain-relieving potential of the formulation.

- **Study of sustained drug action:**

Examines whether the patch can maintain prolonged therapeutic activity.

- **Evaluation of skin compatibility:**

Detects any signs of irritation, redness, or allergic reactions after application.

- **Prediction of clinical performance:**

Provides preliminary information regarding the effectiveness of the formulation in future clinical applications.

14.2 Pharmacological Outcomes

Diclofenac sodium-loaded chitosan–alginate transdermal patches have shown promising pharmacological performance in various studies.

The observed outcomes include:

- **Reduction in inflammation:**

Significant decrease in edema and inflammatory responses.

- **Prolonged therapeutic effect:**

Sustained drug release helps maintain anti-inflammatory activity for longer durations.

- **Improved patient safety:**

Reduced gastrointestinal side effects compared with oral administration.

- **Better skin tolerability:**

Natural polymer-based patches generally show minimal skin irritation.

These findings suggest that chitosan–alginate based transdermal systems may serve as effective alternatives to conventional oral diclofenac therapy for long-term management of musculoskeletal disorders.

Graph 4. Patient Adherence Comparison

Therapy	Adherence (%)
Oral NSAIDs	58
Conventional Gel	71
Synthetic Patch	83
Natural Polymer TDDS	92



Graph 5. Skin Irritation Comparison

Formulation	Draize Score
Synthetic Patch	2.8
Alcohol-Based Gel	2.1
Natural Polymer Patch	0.3



15. Advantages of Chitosan– Alginate Based Transdermal Drug Delivery Systems

Chitosan-alginate TDDS have been extensively studied in the field of pharmacology due to the potential to deliver drugs effectively and safely using this system. Both of these polymers when combined make up a stable matrix system which improves the properties of transdermal patches both physically and physiologically.

Chitosan-alginate TDDS provide certain benefits compared to the oral administration method such as sustained drug release, minimal side effects, and better skin tolerance. Moreover, both of these polymers being biodegradable and biocompatible in nature can be used for sustained therapeutic purposes.



15.1 Major Advantages of Chitosan–Alginate TDDS

- **Sustained drug release:**

The polymeric matrix provides controlled and prolonged release of diclofenac sodium, helping maintain therapeutic drug levels for extended periods.

- **Reduced systemic side effects:**

Transdermal delivery minimizes gastrointestinal irritation and avoids hepatic first-pass metabolism associated with oral administration.

- **Improved patient compliance:**

Reduced dosing frequency and non-invasive administration improve patient comfort and treatment adherence.

- **Excellent biocompatibility:**

Both chitosan and alginate are naturally derived polymers that are generally well tolerated by the skin and biological tissues.

- **Biodegradable and eco-friendly nature:**

These natural polymers degrade into non-toxic products and are environmentally sustainable.

- **Enhanced skin compatibility:**

Chitosan–alginate patches usually produce minimal skin irritation compared with formulations containing synthetic polymers.

16. Current Challenges and Limitations

Despite having high promise in terms of their therapeutic efficiency, there exist certain drawbacks in chitosan-alginate based transdermal systems that hinder their widespread use in pharmaceutics. The issues include formulation instability, variations in natural polymers, production complexities, and lack of clinical evidence.

It is essential to comprehend these limitations as they may help us develop better transdermal formulations in the future.

16.1 Major Challenges and Limitations

- **Moisture sensitivity:**

Natural polymers such as chitosan and alginate are highly hydrophilic and may absorb moisture from the environment, which can affect patch stability and mechanical properties.

- **Batch-to-batch variability:**

Since these polymers are obtained from natural sources, variations in composition and purity may occur between different batches.

- **Limited mechanical strength:**

Some natural polymer-based patches may show lower mechanical durability compared with synthetic polymer formulations.

- **Drug permeation barrier:**

The stratum corneum still acts as a major obstacle for effective transdermal delivery of certain drugs.

- **Stability issues:**

Changes in temperature, humidity, and storage conditions may influence the physical and chemical stability of the formulation.

- **Scale-up difficulties:**

Maintaining uniformity and consistency during large-scale manufacturing can be challenging.

- **Limited clinical studies:**

Most research is currently limited to laboratory and animal studies, with fewer human clinical evaluations available.

- **Regulatory challenges:**

Standardization and regulatory approval of natural polymer-based transdermal systems remain complex.

Despite these limitations, ongoing advancements in polymer technology, permeation enhancement, and formulation strategies continue to improve the potential of chitosan–alginate based transdermal drug delivery systems for future pharmaceutical applications.

17. Future Perspectives

Transdermal drug delivery systems using chitosan-alginate combinations for diclofenac sodium have exhibited promising results in enhancing the delivery of diclofenac sodium as well as many other drugs. Further developments in the pharmaceutical industry and biomaterials research will help improve these delivery systems in terms of their efficacy, stability, and applications. Future developments in research will be geared towards improving drug permeation, stability, patient acceptance, and mass production.

The combination of modern drug delivery technologies with the use of natural polymers may result in more effective therapies for chronic inflammation and musculoskeletal diseases.

17.1 Emerging Future Approaches

- **Nanotechnology-based transdermal systems:**

Incorporation of nanoparticles, nanoemulsions, and nanogels may improve drug solubility, skin permeation, and controlled drug release.

- **Microneedle-assisted delivery:**

Microneedle systems can temporarily create microscopic channels in the skin, enhancing drug penetration without causing significant pain.

- **Smart transdermal patches:**

Development of responsive patches capable of controlling drug release according to physiological conditions may improve therapeutic outcomes.

- **Combination polymer systems:**

Use of hybrid natural and synthetic polymers may enhance mechanical strength, stability, and drug release behavior.

- **Improved permeation enhancers:**

Future studies may focus on safer and more effective natural permeation enhancers with minimal skin irritation.

- **Personalized drug delivery systems:**

Customized transdermal formulations based on individual patient needs may improve therapeutic effectiveness and patient compliance.

- **Advanced clinical studies:**

More human clinical trials are needed to establish long-term safety, efficacy, and commercial applicability of these systems.

- **Large-scale industrial production:**

Future research may focus on improving manufacturing techniques for consistent and cost-effective large-scale production.

With continued advancements in biomaterials and pharmaceutical technologies, chitosan–alginate based transdermal systems are expected to become promising alternatives for safer and more effective long-term drug delivery.



18. Conclusion

Transdermal drug delivery systems loaded with diclofenac sodium using chitosan and alginate as polymer matrices present a significant technological breakthrough in the realm of controlled and targeted drug delivery. Use of biopolymers such as chitosan and sodium alginate results in numerous benefits from a pharmaceutical standpoint, namely biocompatibility, biodegradability, film-forming properties, and controlled release capabilities. Formation of the polyelectrolyte complex between the chitosan and alginate polymers results in greater efficacy and robustness of the resulting transdermal patches.

Compared to the traditional oral delivery route, transdermal delivery offers several benefits in the delivery of diclofenac sodium. These include absence of first-pass effect, minimization of adverse effects on the digestive

system, extended pharmacological activity, and enhanced patient compliance. Moreover, the use of natural permeation enhancers, such as menthol and nerolidol, results in greater skin penetration and dermatological safety.

The efficacy of chitosan-alginate-based transdermal drug delivery systems in controlling the release of diclofenac sodium has been shown in various studies such as physicochemical characterization, in vitro drug release, ex vivo permeation studies, and in vivo pharmacological experiments. Such results imply that transdermal systems based on natural polymers might be considered as an alternative to traditional treatment methods, which could be more beneficial for patients with chronic pain and inflammation conditions of musculoskeletal structures.

Despite some existing issues related to system stability, production processes, and lack of clinical trials, further developments in the fields of biomaterials, nanotechnology, and transdermal drug delivery systems will make it possible to enhance the therapeutic properties of these systems. In general, chitosan-alginate-based transdermal systems possess promising perspectives in developing pharmaceuticals.

References

1. Barry BW. Novel mechanisms and devices to enable successful transdermal drug delivery. Eur J Pharm Sci. 2001;14:101–114.
2. Berger J, Reist M, Mayer JM, Felt O, Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm. 2004;57:35–52.
3. Bhatt P, et al. Transdermal drug delivery systems: An overview. Int J Pharm Investig. 2012;2:2–11.
4. Cilurzo F, Minghetti P, Casiraghi A, Montanari L. Drug release and permeability studies of transdermal systems. AAPS PharmSciTech. 2007;8:E1–E7.
5. Guy RH, Hadgraft J. Transdermal Drug Delivery. Marcel Dekker; 2003.
6. Illum L. Chitosan and its use as a pharmaceutical excipient. Pharm Res. 1998;15:1326–1331.
7. Felt O, Buri P, Gurny R. Chitosan: a unique polysaccharide for drug delivery. Drug Dev Ind Pharm. 1998;24:979–993.
8. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56:603–618.
9. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26:1261–1268.
10. Hadgraft J. Skin deep. Eur J Pharm Biopharm. 2004;58:291–299.
11. Brown MB, Martin GP, Jones SA, Akomeah FK. Dermal and transdermal drug delivery systems. Drug Deliv. 2006;13:175–187.
12. Mitragotri S. Breaking the skin barrier. Nat Rev Drug Discov. 2005;4:255–260.
13. Finnin BC, Morgan TM. Transdermal penetration enhancers. J Pharm Sci. 1999;88:955–958.
14. Moghadam SH, Saliaj E, Wettig SD, et al. Effect of chemical permeation enhancers on skin permeability. Int J Pharm. 2013;447:36–41.
15. Chien YW. Novel Drug Delivery Systems. 2nd ed. Marcel Dekker; 1992.
16. Jain NK. Controlled and Novel Drug Delivery. CBS Publishers; 2018.
17. Robinson JR, Lee VHL. Controlled Drug Delivery Fundamentals. Marcel Dekker; 1987.
18. Aulton ME. Aulton's Pharmaceutics. Elsevier; 2018.
19. Allen LV, Popovich NG, Ansel HC. Pharmaceutical Dosage Forms and Drug Delivery Systems. LWW; 2014.
20. Lachman L, Lieberman HA, Kanig JL. Theory and Practice of Industrial Pharmacy. CBS Publishers; 2013.

21. Sinko PJ. Martin's Physical Pharmacy and Pharmaceutical Sciences. LWW; 2011.
22. Florence AT, Attwood D. Physicochemical Principles of Pharmacy. Pharmaceutical Press; 2016.
23. Remington JP. Remington: The Science and Practice of Pharmacy. Pharmaceutical Press; 2020.
24. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release. Acta Pol Pharm. 2010;67:217–223.
25. Korsmeyer RW, Gurny R, Doelker E, et al. Mechanisms of drug release from polymeric systems. Int J Pharm. 1983;15:25–35.
26. Higuchi T. Mechanism of sustained-action medication. J Pharm Sci. 1963;52:1145–1149.
27. Peppas NA, Bures P, Leobandung W, Ichikawa H. Hydrogels in pharmaceutical formulations. Eur J Pharm Biopharm. 2000;50:27–46.
28. George M, Abraham TE. Polyionic hydrocolloids for protein drug delivery. J Control Release. 2006;114:1–14.
29. Nayak AK, Pal D. Natural polymers in transdermal drug delivery systems. Int J Pharm Sci Rev Res. 2016;38:1–7.
30. Patel D, Chaudhary SA, Parmar B, Bhura N. Transdermal drug delivery systems: a review. Pharm Innov J. 2012;1:66–75.
31. Rathi V, Saraf S. Formulation and evaluation of transdermal systems. Int J PharmTech Res. 2011;3:29–35.
32. Kumar R, Philip A. Modified transdermal technologies. Indian J Pharm Sci. 2020;82:567–580.
33. Patel P, Kumar S. Occupational musculoskeletal disorders in Indian workers. Indian J Occup Environ Med. 2019;23:65–71.
34. Singh A, Sharma D, Verma R. Economic burden of musculoskeletal disorders in India. Indian J Public Health. 2023;67:45–53.
35. WHO. Adherence to Long-Term Therapies: Evidence for Action. World Health Organization; 2003.
36. WHO Global Health Estimates. World Health Organization; 2023.
37. Roth GA, Mensah GA, Johnson CO, et al. Global burden of musculoskeletal diseases. Lancet. 2021;398:1605–1658.
38. Luo Y, Yin P. Global epidemiological trends in musculoskeletal disorders. Front Public Health. 2025;13:115–127.
39. Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of NSAIDs. BMJ. 2011;342:c7086.
40. Lanas A, Hunt R. Prevention of anti-inflammatory drug-induced gastrointestinal damage. Gastroenterology. 2006;130:1885–1899.
41. Mason L, Moore RA, Edwards JE, et al. Topical NSAIDs for chronic musculoskeletal pain. BMC Musculoskelet Disord. 2004;5:28.
42. Wokovich AM, Prodduturi S, Doub WH, Hussain AS, Buhse LF. Transdermal drug delivery system evaluation. Drug Dev Ind Pharm. 2006;32:1–10.
43. Potts RO, Guy RH. Predicting skin permeability. Pharm Res. 1992;9:663–669.
44. Cevc G. Lipid vesicles and colloids as drug carriers. Adv Drug Deliv Rev. 2004;56:675–711.
45. Park JH, Saravanakumar G, Kim K, Kwon IC. Targeted drug delivery systems. Adv Drug Deliv Rev. 2010;62:28–41.
46. Gupta R, Rai B. Natural polymeric biomaterials in pharmaceutical formulations. Int J Biol Macromol. 2017;95:102–118.
47. Rangari VD. Pharmacognosy and Phytochemistry. Career Publications; 2015.
48. Vyas SP, Khar RK. Controlled Drug Delivery Concepts and Advances. Vallabh Prakashan; 2012.

49. Rowe RC, Sheskey PJ, Quinn ME. Handbook of Pharmaceutical Excipients. Pharmaceutical Press; 2009.
50. Rathbone MJ, Hadgraft J, Roberts MS. Modified-Release Drug Delivery Technology. Informa Healthcare; 2008.
51. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. 2022.
52. United States Pharmacopeia. USP 43–NF 38. 2020.
53. ICH Guidelines Q1A(R2): Stability Testing of New Drug Substances and Products. 2003.
54. EMA Guideline on Quality of Transdermal Patches. European Medicines Agency; 2019.
55. FDA Guidance for Transdermal and Topical Delivery Systems. US FDA; 2019.
56. OECD Guidelines for Skin Irritation Testing. OECD; 2021.
57. CPCSEA Guidelines for Laboratory Animal Facility. Government of India; 2022.
58. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. World Medical Association; 2013.
59. SPSS Statistical Software Documentation. IBM Corp.; 2024.
60. Kunta JR, Goskonda VR, Brotherton HO, Khan MA, Reddy IK. Effect of menthol and related terpenes on the permeation of diclofenac sodium across excised skin. Drug Dev Ind Pharm. 2008;34:583–592.